Prostat Kanserli Hastalarda Bilateral Orkiektomi ile Bilateral Orkioktemi - CPA Tedavisinin Karşılaştırılması

Year 1992, Volume: 45 Issue: 4, 769 - 776, 31.12.1992

Hamit Ersoy

Abstract

D evresindeki 32 prostat kanserli hastadan 16'sına bilateral orkiektomi kalan 16'sına da bilateral orkiektomi ile birlikte anti-androjen olan cypteron acetate (CPA) (100mg/gün) vererek anti androjen tedavinin klinik etkinliklerini araştırdık. Orkiektomi grubunda ilk yılda %67 CPA grubunda ise %75 başarılı yanıt alındı. İkinci yılda ise grupta %58 diğer grupta %43 oranında progresyon görüldü. Literatür uyumlu olarak CPA ile kombine anti-androjen tedavinin cerrahi kastrasyona üstünlüğünü gözlemedik. Ancak CPA grubunda sıcak basması gibi komplikasyonların anlamlı olarak azlığı tedaviye bu yönde üstünlük kazandırıyordu.

Keywords

prostat kanseri , anti-androjen tedavi , cypteron asetat

Project Number

-

COMPARISON OF BILATERAL ORCHIECTOMY WITH BILATERAL ORCHIECTOMY-CPA TREATMENT IN PATIENTS WITH PROSTATE CANCER

Abstract

We investigated the clinical efficacy of anti-androgen therapy by giving 16 patients with bilateral orchiectomy and the remaining 16 patients with bilateral orchiectomy and cypteron acetate (CPA) (100 mg/day), an antiandrogen. In the first year, 67% of the patients in the orchiectomy group and 75% in the CPA group were successful. In the second year, 58% of the patients in the group and 43% in the other group were seen to progress. Consistent with the literature, we did not observe the superiority of combined anti-androgen therapy with CPA over surgical castration. However, the significant decrease in complications such as hot flashes in the CPA group gave the treatment an advantage in this respect.

Keywords

Prostate Cancer , antiandrogen therapy , cyproterone acetate

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Becker Klosterhalfen H : Clinical experience with Androcur in the treatment of prostatic cancer. In H, Klosterhalfen (ed) : New Developments in Biosciences 4. sayfa 97 Waiter de gruyter Berlin, 1988.
• 2. Catalona WJ Scott WW : Carcinoma of prostate. Campbell's Urology, 5Th ed. vol. 2 Philadelphia : WB Saunders. 1986.
• 3. Di in in Silverio F Sciarra F : Result of long term treatment with cyproterne acetate advanced prostatic cancer patients. In Kiosterhalfen (ed) : New Developments Biosciences 4 sayfa 115 Waiter de Gruyter Berlin, 1088.
• 4. Geller J Albert J Yen SSC : Medical, castration of males with megestrol acetate and small doses of diethylstilbestrol. J. Clin. Endoc. Metab. 52 : 576, 1981.
• 5. Klugo RC Farah RN Cerny JC : Bilateral orchiectomi for carcinoma of prostate. Responses of serum testesterone and clinical response to subsequent estrogen therapy. Urology, 17 : 49, 1981.
• 6. Labrie F Dupond A Belanger A Lachance R: Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with LHRH agonist. J. Urol 1987 : 188, 804.
• 7. Neumann F Radimaier A Borcmacher K : llerlemis prostat. kanserinin hormonal tedavisi, Schering (basin).
• 8. Resnick MI Grayhack JT : Treatment of stage IV carcinoma of prostate. Urol. Clin N. Amer, 2 (1975) 141.
• 9. Schroeder FH Klijn JG John FH : Metastatic cancer of the prostate managed by buserelin acetate versus buserelin acetate plus cyproterne acetate. J. Urol 1986, 135 : Ozet 392.
• 10. Tunn UW : Rationale of total androjen blockade by cyproterne acetate. In H. Klosterhalfen (ed) : New Developments in Biosciences 4. sayfa 87 Walter de Gruyter Berlin, 1988.
• 11. Wein J Alan Malkowicz S Bruce : Cancer of the Prostate Part IV sayfa 23, Schering Plough International, 1990.